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S
evere microangiopathic hemolytic anemia and
thrombocytopenia during pregnancy or during
the postpartum period requires a differential diagnosis
between hemolysis, elevated liver enzymes, low
platelets (HELLP) syndrome, thrombotic thrombocy-
topenic purpura, and complement-mediated throm-
botic microangiopathy. The 3 diseases may merge
into one another, overlap syndromes are increasingly
described, and the differential diagnosis may some-
times be allowed only by genetic analysis.1,2
Atypical hemolytic uremic syndrome (aHUS) is a rare
variant accounting for 5%–10% of all cases of HUS; it is
characterized by an increased activity of the alternative
pathway of the complement caused by an acquired or
genetic dysregulation.3 Genetic causes include different
mutations in regulatory complement genes. The most
common loss of function mutations involve complement
factor H (CFH) and CFH-related hybrid genes (CFHR1–
CFHR5), complement factor I (CFI), and monocyte che-
moattractant protein (MCP); gain of functionmutations of
complement-activating genes, such as complement factor
B (CFB) or C3, are less common. Overall, pathogenic
mutations are described in 50%–60% of patients with
aHUS and mainly regard CFH.3
aHUS is a highly heterogeneous disease: different
haplotypes in complement genes and various pathogenicInternational Reports (2020) 5, 1603–1607genetic variants determine different levels of alternative
pathway activity, as measured by different tests, and
modulate the risk of developing aHUS and its severity.
Pregnancy has been identified as an important
trigger for aHUS, with a reported incidence of 1 in
25,000 gestations. The majority of cases present in the
postpartum period, although pregnancy-associated
aHUS (p-aHUS) may develop during pregnancy.4,5
p-aHUS is a severe disease, with high maternal mor-
tality, a risk of fetal loss, and a risk of rapid progression
to end-stage renal disease (ESRD).4,5
Conventional management of aHUS, including
plasma exchange and hemodialysis in patients with
severe acute kidney injury, may not be effective in
patients with severe or recurrent disease.6 Eculizumab,
a humanized monoclonal antibody directed against C5,
is presently the gold standard treatment to control the
overamplification of complement alternative pathway,
and a growing body of literature supports its use in
p-aHUS.7–9
The largest available series of patients with p-aHUS
reports on 87 patients diagnosed from 1983 to 2013. In
this multicenter cohort, only 4 patients observed since
2011 received eculizumab as second-line therapy after
plasma exchanges, with complete kidney function re-
covery in 3 patients. Overall, genetic mutations were
detected in 49 (56%) patients, mainly concerning CFH
(30%) and CFI (9%).4 Before eculizumab became1603
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corticosteroids; the prognosis was grim, leading to
ESRD in 53% of cases and to predialytic chronic kid-
ney disease in 19% of cases. Twenty-eight percent of
patients relapsed over a mean follow-up of 7.2 years,
including half of those who had received a kidney
transplant.4 Fetal or neonatal death occurred in 14% of
cases, and dialysis was required, at least temporarily, in
71% of patients.4
The case here described may stress the importance of
early diagnosis and prompt treatment but suggests also
that the challenge of pregnancy may represent a unique
occasion for the diagnosis of rare diseases.CASE PRESENTATION
We describe the case of a 39-year-old woman who
developed p-aHUS during a twin pregnancy.
The patient’s family history was negative for renal
or other relevant diseases. The patient underwent
in vitro fertilization resulting in twin pregnancy,
whose development was unremarkable until gestational
week 32, when she was referred to the obstetrics and
gynecology unit for hypertension (blood pressure, 150/
95 mm Hg). At referral, her serum creatinine level was
1.05 mg/dl, no proteinuria was detected at urinalysis,
hemoglobin was 13.8 g/dl, haptoglobin was 30 mg/dl,
and the platelet count was slightly lower than normal
(139  103/ml); liver enzymes were normal as were
uterine and umbilical Doppler flows; gestational hy-
pertension was therefore diagnosed, on the account of
the lack of proteinuria; however, in retrospect, a mild
increase in serum creatinine was overlooked.S1–S3
The patient was started on a-methyldopa (250 mg
twice a day), but 4 days later she presented to the
hospital complaining of strong epigastrium pain.
Elevated liver enzymes (aspartate aminotransferase,
1575 U/l; alanine aminotransferase, 1175 U/l), acute
hemolytic anemia (hemoglobin 9.5 g/dl), increased
lactate dehydrogenase (5574 U/l), and thrombocyto-
penia (platelets, 61  103/ml) were found, in addition to
persistent hypertension. Serum creatinine and urea
were still in the normal range, but urinalysis demon-
strated high-grade proteinuria with a high albumin-to-
creatinine ratio (300 mg/g). The diagnosis of HELLP
syndrome was made and Cesarean section was per-
formed, giving birth to healthy dizygotic twins,
weighing 2.190 Kg (97 percentile) and 2.050 Kg (90
percentile).
After Cesarean section, severe bleeding occurred,
and subtotal hysterectomy was needed. The patient
was admitted to the intensive care unit. Her blood
pressure remained high (180/110 mm Hg) and anemia
persisted despite blood transfusions. She was treated1604by plasma infusion on postpartum days 1 and 2
(4 units of frozen fresh plasma). Nephrology was con-
sulted 5 days postpartum because of a rapid increase in
serum creatinine (up to 5.5 mg/dl), worsening of ane-
mia (hemoglobin 6.6 g/dl) with low haptoglobin level
(30 mg/dl) and low platelets (174  103/ml) with high
lactate dehydrogenase levels (1150 U/l). Schistocytes
were not found in the peripheral smear. ADAMTS-13
activity assay was not feasible because of the interfer-
ence with the previous plasma infusions. However, the
lack of response to plasma infusion and the low C3 level
(53 mg/dl) suggested p-aHUS; on account of the severity
of the clinical picture, eculizumab was started according
to the protocol described by Fakhouri et al.,S4 which
consisted of intravenous infusion of 900mgof eculizumab
every week for 4 weeks, followed by 1200 mg every 2
weeks.
After the first eculizumab infusion the clinical con-
ditions and laboratory tests rapidly and dramatically
improved. Treatment with eculizumab was continued
for 1 year and discontinued thereafter (Figure 1). One
year after discontinuation, kidney function remained
normal (Chronic Kidney Disease Epidemiology Collab-
oration estimated glomerular filtration rate, 98 ml/min
per 1.73 m2) without proteinuria or hematuria; the
children are on regular pediatric follow-up and have
attained the expected developmental milestones.
Genetic Analysis
After acquiring written informed consent, genetic
analysis was performed by direct sequencing to
investigate the genetic variants coding for proteins
regulating alternative complement pathway, as CFH,
MCP, C3, CFI, CFB, and THBD, using primers yet
described in the published literature.S5,S6 Resulting
sequences were evaluated with Sequencher software
(Gene Codes Corporation, Ann Arbor, MI).
We identified a novel heterozygous G-to-A mutation
[NM_000186.3(CFH): c.1873þ1G>A] in CFH that has
never been described in the Human Gene Mutation
Database (www.hgmd.cf.ac.uk/ac/index.php) nor in
the 1000 Genomes database (ftp://ftp.1000genomes.ebi.
ac.uk/vol1/ftp/).
In addition, we identified other variants in the genes
that encode the alternative pathway of complement that
have already been described in the database (http://www.
fh-hus.org/). In particular, we identified a H3 risk haplo-
type for aHUS on the CFH gene3 and 2 genetic variants on
the MG3 region of C3 [NM_000064.3(C3): c.1001T>C
p. Prol314Leu], and the CFI gene [NM_000204.4 (CFI):
c.898G>A p.Ala300Thr]. Conversely, MPC, CFB, and
THBD genes resulted wild type.
To confirm the abnormal splicing according to the
standard protocol,S7 we extracted the RNA fromKidney International Reports (2020) 5, 1603–1607
Figure 1. Trend of biochemical parameters (creatinine [a], hemoglobin [b], platelets [c], and lactate dehydrogenase [LDH; d]) after delivery.
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(C) and from our patient (P) and performed reverse
transcriptase–polymerase chain reaction using primer
sequences to amplify the region between exons 12 and 13
of CFH. Reverse transcriptase–polymerase chain reaction
generated a single fragment of 486 bp in the control
subject, while in the patient reverse transcriptase–Figure 2. Analysis of the splice mutation IVS12þ1G>A [NM_000186.3(CF
action from the control (C) (line 1) generated a single band of 486 bp. Re
carrying a heterozygous IVS12þ1G>A mutation (line 2) generated a 320-bp
3ʹ end of exon 12. IVS, intervening sequence; MW, molecular weight.
Kidney International Reports (2020) 5, 1603–1607polymerase chain reaction displayed also a 320-bp band
(Figure 2a), that was sequenced and revealed a 166-bp
deletion of the 3ʹ end of exon 12 (Figure 2b).
The splicing defect would lead to loss of 55 amino
acids, a change in reading frame, and a premature
termination codon in exon 13. This transcript may
undergo nonsense-mediated decay and could thereforeH): c.1873þ1G>A]. (a) Reverse transcriptase–polymerase chain re-
verse transcriptase–polymerase chain reaction from the patient (P)
band that was sequenced (b) and revealed a 166-bp deletion of the
1605
Table 1. Teaching points
Microangiopathic hemolytic anemia and thrombocytopenia during pregnancy or the
postpartum period requires a differential diagnosis between HELLP syndrome, TTP, and
complement-mediated TMA or HUS.
This differential diagnosis is not easy, because HELLP, TTP, and TMA or HUS may merge
into one another, and overlap syndromes are described.
Atypical hemolytic uremic syndrome is a rare variant of HUS characterized by an
increased activity of the alternative pathway of the complement. Genetic causes include
mutations in different regulatory complement genes.
Differential diagnosis analysis may be possible only by genetic analysis, considering that
new mutations are continuously reported.
Timely treatment with eculizumab may be critical to prevent irreversible kidney damage.
HELLP, hemolysis, elevated liver enzymes, low platelets; HUS, hemolytic uremic syn-
drome; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.
NEPHROLOGY ROUNDS D Santoro et al.: Atypical HUS in Pregnancylead to haploinsufficiency of CFH products or lead to
an abnormal protein missing residues 570–1231. The
most likely outcome from this canonical splice variant
is skipping of exon 12. Skipping of exon 12 would be
in-frame and lead to only the deletion of residues
encoded by exon 12. This transcript would not un-
dergo nonsense-mediated mRNA decay, and could
possibly retain some function depending on what is
lost. Repeating the reverse transcriptase–polymerase
chain reaction experiment with 1 primer upstream
and 1 downstream of exon 12 is planned, to further
characterize the anomaly in our patient.DISCUSSION
Pregnancy is an important trigger for several immu-
nologic diseases and represents an important occasion
for diagnosis by giving a chance of advancing the
understanding of their pathogenesis. Many kidney and
immunologic diseases present with a clinical picture
that is initially interpreted as belonging to the spec-
trum of the hypertensive disorders of pregnancy. This
case may be an example of the importance of the dif-
ferential diagnosis between pre-eclampsia–HELLP,
primary thrombotic microangiopathy, such as p-aHUS
or thrombotic thrombocytopenic purpura, and overlap
cases, which may be more frequent than previously
thought; notably, this case gave the occasion for
discovering a potentially pathogenic genetic variant of
the complement pathway that has not been previously
described.S8
Data reported in the literature show that about 70%
of CFH mutations identified in patients with dysregu-
lation of complement alternative pathway are hetero-
zygous and located on short consensus repeats (SCR)
19-20, resulting in a CFH unable to exert its regulatory
activity, especially on endothelial cells and platelets. To
date, few mutations have been identified in the
remaining domains.3
We report here a newCFH splicingmutation located in
a domain never previously involved in the development
of p-aHUS. Of note, the splicing mutation causes a partial
deletion of exon 12 that should affect SCR 10 central
modules, leading to a misfolding similar to the bend of a
hinge, which appear to be more compact than wild-type
central SCR conformation and whose functional role has
not yet been elucidated.S9We speculate that the mutation
found in our patient affects the CFI-mediated regulatory
activity, contributing to massive fluid-phase activation of
the alternative complement pathway. The clinical
phenotype of our patient is probably the result of a strong
environmental trigger (twin pregnancy) and of her ge-
netic background; of note, she is also carrier of a C3
variant already described in the literature but whose1606pathogenic role is not well established, which is located
in the conserved and only partially known MG3
domain.S9
Finally, according to what has been reported in the
published literature, aHUS risk haplotype H3
[NM_000186.3(CFH)er SNPs 331C>T (rs3753394),
c.184G>A Val62Ile (rs800292), c.1204T>C p.Tyr402His
(rs1061170), c.2016A>G p.Gln672Gln (rs3753396),
IVS15 543G>A intron 15 (rs1410996) and c.2808G>T
p.Glu936Asp (rs1065489)],S10 together with the 2 mu-
tations, may increase the penetrance of disease.3
The rapid and almost complete kidney function re-
covery, with rapid rise in both hemoglobin and
platelets levels after the first eculizumab administration
led to continue this therapy for a year. During this
follow-up period, the estimated glomerular filtration
rate was normal and the patient did not develop hy-
pertension or urinary abnormalities. Moreover, we
considered that her pregnancy had triggered aHUS; the
patient could not have additional pregnancies because
of the hysterectomy, and therefore eculizumab was
discontinued after 1 year of treatment. Normalization of
the kidney function persists 1 year later.
In conclusion, our case underlines the importance
of considering thrombotic microangiopathy in the
differential diagnosis of hemorrhagic and micro-
angiopathy syndromes in pregnancy and puerperium
(Table 1). The relationship with hypertensive disor-
ders of pregnancy, and in particular with HELLP
syndrome, is not fully clear, and a clear-cut differ-
entiation is not always feasible; the encouraging re-
sults obtained with eculizumab in some severe cases
of HELLP syndrome further underline the pathogen-
esis overlap. S11–S13
From a diagnostic point of view, our case suggests
that in patients affected by aHUS sequencing should
not be limited to hot spot regions because new muta-
tions may be identified in uncommon domains, and
these domains may be of high relevance for both pa-
tients and their offspring. From the clinical point of
view, our case suggests that timely treatment, based onKidney International Reports (2020) 5, 1603–1607
D Santoro et al.: Atypical HUS in Pregnancy NEPHROLOGY ROUNDSclinical data, even before the genetic confirmation, has
probably prevented irreversible kidney damage.S14,S15
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